Polycythemia Vera

Oncology·MeSH: Polycythemia Vera

Prevalence

30.0 / 100K

18 drugs in development·15 companies·14 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
vonjo	CTI BIOPHARMA CORP (CTIC)

Phase 3(3)

Drug	Company
Rusfertide	Protagonist Therapeutics, Inc (PTGX)
sapablursen	Deciphera Pharmaceuticals, Inc. (DCPH)
sapablursen	Eton Pharmaceuticals, Inc. (ETON)

Phase 2(6)

Drug	Company
bomedemstat	Imago BioSciences, Inc. (IMGO)
disc-0998	Disc Medicine, Inc. (IRON)
Divesiran	Silence Therapeutics Plc (SLN)
rusfertide	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
rusfertide	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
sapablursen	IONIS PHARMACEUTICALS INC (IONS)

Phase 1(2)

Drug	Company
disc-3405	Disc Medicine, Inc. (IRON)
prt12396	Prelude Therapeutics Inc (PRLD)

Preclinical(4)

Drug	Company
JAK2 program	Cogent Biosciences, Inc. (COGT)
Licensed siRNA targeting TMPRSS6	AGIOS PHARMACEUTICALS, INC. (AGIO)
PN-8047	Protagonist Therapeutics, Inc (PTGX)
rlyb332	Rallybio Corp (RLYB)

Phase 1/Phase 2(1)

Drug	Company
sln124	Silence Therapeutics Plc (SLN)

Phase 4(1)

Drug	Company
Hydroxyurea	Novartis AG (NVS)

BioSniper tracks 18 drugs in development for Polycythemia Vera across 15 companies.

There are 14 clinical trials targeting Polycythemia Vera tracked by BioSniper.

The estimated prevalence of Polycythemia Vera is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.